Fabry Nephropathy
Carregando...
Arquivos
Fontes externas
Fontes externas
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Capítulo de livro
Direito de acesso
Arquivos
Fontes externas
Fontes externas
Resumo
One of the main features of Fabry disease (FD) is insidious and progressive Fabry Nephropathy. These patients should have the same general measures as all patients with proteinuric kidney disease, such as control of proteinuria and hypertension, salt restriction, and modification of lifestyle, in addition to specific therapy. Specific therapy should be individualized for each patient in a sharing decision with the patient and his family. Enzyme replacement therapy (ERT) is appropriate for all patients with FD, regardless of the type of the GLA variant. Chaperone therapy is a choice only for patients with amenable variants and should not be used in patients with eGFR < 30 mL/min/1.73m2 and/or those under 16 years old. Finally, emerging therapies are under research, including next-generation ERT (pegunigalsidase alfa, moss-derived α-galactosidase A), substrate reduction therapy (lucerastat, venglustat), mRNA therapy, and gene therapy, which may provide better control of Fabry disease in the future.
Descrição
Palavras-chave
Chronic kidney disease, Fabry disease, Nephropathy, Rare diseases
Idioma
Inglês
Citação
Amyloidosis and Fabry Disease: a Clinical Guide, p. 325-347.
